
Johnson & Johnson
NYSE:JNJ

Intrinsic Value
The intrinsic value of one
JNJ
stock under the Base Case scenario is
138.09
USD.
Compared to the current market price of 163.42 USD,
Johnson & Johnson
is
Overvalued by 15%.
The Intrinsic Value is calculated as the average of the two valuation methods:

Fundamental Analysis
JNJ Profitability Score
Profitability Due Diligence
Johnson & Johnson's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
Johnson & Johnson's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
JNJ Solvency Score
Solvency Due Diligence
Johnson & Johnson's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Johnson & Johnson's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Johnson & Johnson
JNJ Capital Structure
Johnson & Johnson
Market Capitalization | 428B USD | |
Total Debt | 31.5B USD | |
Minority Interest | 0 USD | |
Preferred Equity | 0 USD | |
Cash and Equivalents | 5.6B USD | |
Short-Term Investments | 28.5B USD | |
Enterprise Value | 425B USD |
Wall St
Price Targets
JNJ Price Targets Summary
Johnson & Johnson
According to Wall Street analysts, the average 1-year price target for
JNJ
is 188.75 USD
with a low forecast of 161.6 USD and a high forecast of 225.75 USD.
Competitive Landscape
JNJ Competitors
Johnson & Johnson
JNJ Suppliers & Customers
Johnson & Johnson
Johnson & Johnson has 171 key suppliers from 18 countries and 28 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.
Johnson & Johnson has 61 key customers from 12 countries and 10 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.
Ownership
JNJ Insider Trading
Buy and sell transactions by insiders
During the last 12 months Johnson & Johnson insiders have not bought any shares, and sold 81.3M USD worth of shares. The last transaction was made on Feb 6, 2023 by Wolk Joseph J (Exec VP, CFO), who sold 2.7M USD worth of JNJ shares.
Shareholder Return
JNJ Price
Johnson & Johnson
Average Annual Return | 9.88% |
Standard Deviation of Annual Returns | 7.55% |
Max Drawdown | -27% |
Market Capitalization | 428B USD |
Shares Outstanding | 2 614 479 872 |
Percentage of Shares Shorted | 0.48% |
Company Profile

Country
Industry
Market Cap
Dividend Yield
Description
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in New Brunswick, New Jersey and currently employs 141,700 full-time employees. The firm operates through three segments: Consumer Health, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.
Contact
IPO
Employees
Officers
The intrinsic value of one
JNJ
stock under the Base Case scenario is
138.09
USD.
Compared to the current market price of 163.42 USD, Johnson & Johnson is Overvalued by 15%.